European Pharmaceutical Manufacturer: What’s on at BIO?

Matt Stober, CEO

What are you most looking forward to at BIO? 

At BIO, our scientific and commercial leadership are eager to meet customers face-to-face to learn how shifting geopolitical and supply-chain dynamics are influencing their pipelines and discuss how Abzena’s fully integrated US & UK network can assist in keeping their critical programs on track. From concept to commercialization, our end-to-end biologics and bioconjugates services model delivers fewer handoffs, more transparent communication, and faster decisions — advantages that matter when markets are volatile. We expect to leave Boston with fresh collaboration opportunities and sharper insight into how we can better assist our customers’ life-changing therapies.

What are you showcasing at this year’s event? 

We’re spotlighting the power of our AbZelectPRO™ cell line development platform, and our next-generation site-specific conjugation technology, ThioBridge. Our enhanced AbZelectPRO™ platform, cuts DNA-to-Research Cell Bank timelines to just 10 weeks, delivering highly stable titres up to 8g/L.  While our ThioBridge™ technology improves the design and delivery of ADCs, AOCs, and RDCs by providing a more uniform DAR profile, stable linker attachment, and improved pharmacokinetic properties. These state-of-the-art solutions are designed to de-risk and streamline our customers’ programs from preclinical into the clinic with greater success.

Read the full article here